Differences in the efficacy and safety of eribulin in patients with soft tissue sarcoma by histological subtype and treatment line

Nakano,Kenji; Hayakawa,Keiko; Funauchi,Yuki; Tanizawa,Taisuke; Ae,Keisuke; Matsumoto,Seiichi; Tomomatsu,Junichi; Ono,Makiko; Taira,Shinichiro; Nishizawa,Masatoshi; Wang,Xiaofei; Ohmoto,Akihiro; Sato,Yasuyoshi; Fukuda,Naoki; Urasaki,Tetsuya; Takahashi,Shunji

doi:10.3892/mco.2020.2175

January-2021 Volume 14 Issue 1

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

January-2021 Volume 14 Issue 1

Full Size Image

Article Open Access

Differences in the efficacy and safety of eribulin in patients with soft tissue sarcoma by histological subtype and treatment line

Authors:
- Kenji Nakano
- Keiko Hayakawa
- Yuki Funauchi
- Taisuke Tanizawa
- Keisuke Ae
- Seiichi Matsumoto
- Junichi Tomomatsu
- Makiko Ono
- Shinichiro Taira
- Masatoshi Nishizawa
- Xiaofei Wang
- Akihiro Ohmoto
- Yasuyoshi Sato
- Naoki Fukuda
- Tetsuya Urasaki
- Shunji Takahashi
View Affiliations / Copyright

Affiliations: Department of Medical Oncology, Cancer Institute Hospital of The Japanese Foundation for Cancer Research, Tokyo 135‑8550, Japan, Department of Orthopedic Oncology, Cancer Institute Hospital of The Japanese Foundation for Cancer Research, Tokyo 135‑8550, Japan

Copyright: © Nakano et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
Article Number: 13
|
Published online on: November 25, 2020

https://doi.org/10.3892/mco.2020.2175
Expand metrics +

Abstract

Clinical evidence regarding eribulin treatment for patients with soft tissue sarcoma (STS) is limited to those with L‑sarcoma (leiomyosarcoma and liposarcoma) who have completed at least two chemotherapies. Whether histological subtypes and treatment lines affect the efficacy and safety of eribulin for patients with STS has yet to be elucidated. The current study retrospectively reviewed patients with STS receiving eribulin at the Cancer Institute Hospital of JFCR and evaluated the prognostic factors affecting its efficacy and safety by histological diagnoses and treatment lines. A total of 41 patients with STS, including 26 with L‑sarcoma, underwent eribulin treatment. Additionally, a total of and 14 patients, including 12 with L‑sarcoma, received eribulin as a second‑line treatment. The results revealed that patients with L‑sarcoma demonstrated longer progression‑free survival (PFS) rates compared with patients without L‑sarcoma (4.5 vs. 2.3 months; P=0.005). Furthermore, differences in treatment line significantly affected PFS (4.5 months in second‑line treatment vs. 2.4 months in later lines; P=0.037). A high number of patients with L‑sarcoma received eribulin as a second‑line treatment. Regarding safety, several adverse events were reported, such as neutropenia, which were more frequently observed in patients with L‑sarcoma or other patients receiving eribulin as a second‑line treatment. However, most adverse events were tolerable. The clinical efficacy of eribulin was increased in patients with L‑sarcoma, which was similar to previous clinical trials. However, treatment lines could also affect its efficacy. When evaluating the clinical value of eribulin to STS, it is important to consider treatment lines.

View Figures

View References

1	DeVita VT Jr, Lawrence TS and Rosenberg SA: DeVita, Hellman, and Rosenberg's Cancer Principles & Practice of Oncology 11th edition. Lippincott Williams & Wilkins, Philadelphia, PA, 2018.
2	Kawai A, Yonemori K, Takahashi S, Araki N and Ueda T: Systemic therapy for soft tissue sarcoma: Proposals for the optimal use of pazopanib, trabectedin, and eribulin. Adv Ther. 34:1556–1571. 2017.PubMed/NCBI View Article : Google Scholar
3	Schöffski P, Chawla S, Maki RG, Italiano A, Gelderblom H, Choy E, Grignani G, Camargo V, Bauer S, Rha SY, et al: Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: A randomised, open-label, multicentre, phase 3 trial. Lancet. 387:1629–1637. 2016.PubMed/NCBI View Article : Google Scholar
4	Osgood CL, Chuk MK, Theoret MR, Huang L, He K, Her L, Keegan P and Pazdur R: FDA approval summary: Eribulin for patients with unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen. Clin Cancer Res. 23:6384–6389. 2017.PubMed/NCBI View Article : Google Scholar
5	Schöffski P, Ray-Coquard IL, Cioffi A, Bui NB, Bauer S, Hartmann JT, Krarup-Hansen A, Grünwald V, Sciot R, Dumez H, et al: European Organisation for Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group (STBSG) Activity of eribulin mesylate in patients with soft-tissue sarcoma: A phase 2 study in four independent histological subtypes. Lancet Oncol. 12:1045–1052. 2011.PubMed/NCBI View Article : Google Scholar
6	Kawai A, Araki N, Naito Y, Ozaki T, Sugiura H, Yazawa Y, Morioka H, Matsumine A, Saito K, Asami S and Isu K: Phase 2 study of eribulin in patients with previously treated advanced or metastatic soft tissue sarcoma. Jpn J Clin Oncol. 47:137–144. 2017.PubMed/NCBI View Article : Google Scholar
7	Kobayashi E, Naito Y, Asano N, Maejima A, Endo M, Takahashi S, Megumi Y and Kawai A: Interim results of a real-world observational study of eribulin in soft tissue sarcoma including rare subtypes. Jpn J Clin Oncol. 49:938–946. 2019.PubMed/NCBI View Article : Google Scholar
8	Nakamura T, Tsukushi S, Asanuma K, Katagiri H, Ikuta K, Nagano A, Kozawa E, Yamada S, Shido Y, Yamada K, et al: The clinical outcome of eribulin treatment in Japanese patients with advanced soft tissue sarcoma: A Tokai Musculoskeletal oncology consortium study. Clin Exp Metastasis. 36:343–350. 2019.PubMed/NCBI View Article : Google Scholar
9	Blay JY, Schöffski P, Bauer S, Krarup-Hansen A, Benson C, D'Adamo DR, Jia Y and Maki RG: Eribulin versus dacarbazine in patients with leiomyosarcoma: Subgroup analysis from a phase 3, open-label, randomised study. Br J Cancer. 120:1026–1032. 2019.PubMed/NCBI View Article : Google Scholar
10	Demetri GD, Schöffski P, Grignani G, Blay JY, Maki RG, Van Tine BA, Alcindor T, Jones RL, D'Adamo DR, Guo M and Chawla S: Activity of eribulin in patients with advanced liposarcoma demonstrated in a subgroup analysis from a randomized phase III study of eribulin versus dacarbazine. J Clin Oncol. 35:3433–3439. 2017.PubMed/NCBI View Article : Google Scholar
11	Hensley ML, Maki R, Venkatraman E, Geller G, Lovegren M, Aghajanian C, Sabbatini P, Tong W, Barakat R and Spriggs DR: Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: Results of a phase II trial. J Clin Oncol. 20:2824–2831. 2002.PubMed/NCBI View Article : Google Scholar
12	van der Graaf WT, Blay JY, Chawla SP, Kim DW, Bui-Nguyen B, Casali PG, Schöffski P, Aglietta M, Staddon AP, Beppu Y, et al: Pazopanib for metastatic soft-tissue sarcoma (PALETTE): A randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 379:1879–1886. 2012.PubMed/NCBI View Article : Google Scholar
13	Wiemer EAC, Wozniak A, Burger H, Smid M, Floris G, Nzokirantevye A, Sciot R, Sleijfer S and Schöffski P: Identification of microRNA biomarkers for response of advanced soft tissue sarcomas to eribulin: Translational results of the EORTC 62052 trial. Eur J Cancer. 75:33–40. 2017.PubMed/NCBI View Article : Google Scholar
14	Kobayashi H, Okuma T, Oka H, Okajima K, Ishibashi Y, Zhang L, Hirai T, Ohki T, Tsuda Y, Ikegami M, et al: Body composition as a predictor of toxicity after treatment with eribulin for advanced soft tissue sarcoma. Int J Clin Oncol. 24:437–444. 2019.PubMed/NCBI View Article : Google Scholar

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Differences in the efficacy and safety of eribulin in patients with soft tissue sarcoma by histological subtype and treatment line

This article is mentioned in:

Abstract

Figure 1

Figure 2

Related Articles